Investigating inflammation and metabolism after cardiac arrest
Official title: Immunoinflammatory and Metabolic Responses in Post Cardiac Arrest Syndrome (PCAS)
Run by MaineHealth · NCT02664831 · Data updated 2026-11-12
This study looks at how inflammation and metabolism change after cardiac arrest to see if they affect recovery and brain health in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | MaineHealth Academic / other |
| Locations | 1 site (Portland, Maine) |
| Status | Recruiting |
| Started | January 2016 |
| Main results expected | January 2027 |
| Study ends | January 2028 |
| Registry record updated | July 18, 2025 |
| Trial ID | NCT02664831 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have been admitted to the ICU following a cardiac arrest and are unresponsive after resuscitation.
✕Probably not a fit
Patients who are actively dying, unable to provide informed consent within 24 hours of resuscitation, or have severe bleeding issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the molecular mechanisms behind the systemic inflammatory response and metabolic changes following cardiac arrest. By analyzing blood samples from patients over a week, the study will assess how these factors relate to brain injury, survival rates, and functional outcomes. The research focuses on the role of immune cell activity and the presence of brown adipose tissue in influencing recovery and neurological outcomes. The goal is to identify potential therapeutic targets that could improve recovery after cardiac arrest.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies that enhance recovery and neurological outcomes for cardiac arrest survivors.
How similar studies have gone: Preliminary evidence suggests that similar studies have shown promise in understanding the inflammatory processes following cardiac arrest, although this specific approach may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * Admitted to the intensive care unit after cardiac arrest episode * Unresponsive after resuscitation Exclusion Criteria: * Moribund / actively dying at the time of evaluation * Informed consent cannot be obtained within 24 hours of resuscitation * Hemoglobin less than 7.0 g/dL, active high-volume bleeding, or requiring a transfusion
Where it's running
-
Maine Medical Center
Portland, Maine, United States Recruiting
Study contacts
- Principal investigator: Sergey Ryzhov, MD, PhD — MaineHealth Institute for Research
- Study coordinator: David B Seder, MD
- Email: david.seder@mainehealth.org
- Phone: 207-662-2179
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.